Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD3 | Q8IV08 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | TSHR | P16473 | 6/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16029049 | 0.90 | ALDH1A1 (0.55) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL16029479 | 0.89 | TSHR (0.70) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL16029403 | 0.89 | ALDH1A1 (0.70) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL16029352 | 0.88 | ALDH1A1 (0.63) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL16029277 | 0.88 | ALDH1A1 (0.58) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL16029504 | 0.87 | ALDH1A1 (0.56) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL16029321 | 0.86 | ALDH1A1 (0.55) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL19560555 | 0.84 | ALDH1A1 (0.58) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL16029974 | 0.84 | MAPT (0.53) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL16029656 | 0.83 | MAOA (0.60) | PLD3ALDH1A1TSHRNPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| WO-2014152287-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2014152287-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PLD3 2225/4885ALDH1A1 1647/4885TSHR 4540/4885 |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | PLD3 2225/4885ALDH1A1 1647/4885TSHR 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.